Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29706234 | 0.96 | CYP2C19 (0.47) | TPMTCYP2C19ANO1MEN1KMT2A | |
| SCHEMBL16142821 | 0.87 | KDR (0.44) | CYP2C19ANO1MEN1KMT2ALMNA | |
| SCHEMBL16261472 | 0.87 | ANO1 (0.51) | CYP2C19ANO1MEN1KMT2APOLB | |
| SCHEMBL15726940 | 0.87 | ANO1 (0.45) | CYP2C19ANO1MEN1KMT2ALMNA | |
| SCHEMBL570284 | 0.86 | MEN1 (0.49) | MEN1KMT2ALMNAMAPTGAA | |
| SCHEMBL15726944 | 0.84 | ADCY8 (0.46) | ANO1MEN1KMT2AMAPTGAA | |
| SCHEMBL21841652 | 0.82 | RXRA (0.46) | CYP2C19ANO1MEN1KMT2ACACNA1B | |
| SCHEMBL16261376 | 0.81 | ANO1 (0.42) | CYP2C19ANO1MEN1KMT2ALMNA | |
| SCHEMBL3076922 | 0.81 | POLB (0.44) | MEN1KMT2ALMNAMAPTPOLB | |
| SCHEMBL13139932 | 0.81 | JAK2 (0.43) | MEN1KMT2ALMNAMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970106-B1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2018-05-16 | — | — | EP | disclosed |
| US-20140349987-A1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORy, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2014-11-27 | — | — | US | disclosed |
| EP-2463269-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | Intrexon Corporation (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2460786-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | Intrexon Corporation (US) | 2012-06-06 | — | — | EP | disclosed |
| US-7453011-B2 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PROGEN PHARMACEUTICALS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070287754-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PROGEN PHARMACEUTICALS, INC. | 2007-12-13 | — | — | US | disclosed |
| US-7235695-B2 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | SLIL BIOMEDICAL CORPORATION | 2007-06-26 | — | — | US | disclosed |
| US-20060030735-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | CELLGATE, INC. (US) | 2006-02-09 | — | — | US | disclosed |
| US-6982351-B2 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | CELLGATE, INC. (US) | 2006-01-03 | — | — | US | disclosed |
| EP-1453787-A1 | CYCLOALKYL SUBSTITUTED POLYAMINES FOR CANCER THERAPY AND METHODS OF SYNTHESIS THEREFOR | SLIL Biomedical Corporation (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030195377-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | SLIL BIOMEDICAL CORPORATION | 2003-10-16 | — | — | US | disclosed |
| WO-2003050072-A1 | CYCLOALKYL SUBSTITUTED POLYAMINES FOR CANCER THERAPY AND METHODS OF SYNTHESIS THEREFOR | SLIL BIOMEDICAL CORPORATION (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349987-A1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORy, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | RORA, RORB, RORC | TPMT 522/4885CYP2C19 1761/4885ANO1 4647/4885 |
| US-20030195377-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PAICS, DHPS, DHFR | TPMT 1911/4885CYP2C19 3900/4885ANO1 1670/4885 |
| US-20060030735-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PAICS, DHPS, DHFR | TPMT 1911/4885CYP2C19 3900/4885ANO1 1670/4885 |
| US-20070287754-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PAICS, DHPS, DHFR | TPMT 1911/4885CYP2C19 3900/4885ANO1 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.